Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516967 · ClinicalTrials.gov registry record · Phase 3
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
A Phase 3 study, sponsored by Sobi.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
NCT04516967 is a Phase 3 study that has completed, run by Sobi. The registered enrollment target is 75 participants.
The verdict
NCT04516967, a Phase 3 study, has completed, sponsored by Sobi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
Study Summary
A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months
Interventions
- DRUG Placebo
- DRUG Avatrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2025-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04516967
The ClinicalTrials.gov registry entry for NCT04516967 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sobi, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04516967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04516967 about?
NCT04516967 is a clinical study titled "Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months". A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months
What is the current status of trial NCT04516967?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2021-03-05. Estimated completion is 2025-10-28.
What interventions are being tested in trial NCT04516967?
The interventions under investigation include: Placebo (DRUG), Avatrombopag (DRUG).
Who is sponsoring clinical trial NCT04516967?
This trial is sponsored by Sobi, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.